In part 4 of this Exclusive Interview, Dr. Robert Rapaport talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the use of the latest diabetes technology in his practice.Read More »
In part 5, the conclusion of this Exclusive Interview, Dr. Robert Rapaport talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about what he wants healthcare practitioners to understand about transitioning pediatric patients and his goals for his patients' A1C.Read More »
In part 4 of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, CA about the joint effects of SGLT-2 and PCSK9 inhibitors.Read More »
In this week's Homerun Slides, inflammation and immune issues.Read More »
International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #109: Type 2 Diabetes and Cancer Part 2
Links between diabetes and cancer: common risk factors
Epidemiologic studies demonstrate that those with diabetes are more likely to develop cancer, but the mechanisms through which this may occur are incompletely understood. The American Diabetes Association and the American Cancer Society published a consensus report in 2010, with the aim of examining the knowledge regarding the association between diabetes and cancer, exploring the risk factors for both conditions, to examine their possible biologic links and to determine whether certain treatments for diabetes modify cancer risk.
Costs vs. Outcomes for Patients With Type 2 Diabetes: The issue of cost in healthcare is a central point in the discussion of the future of medicine. While much is made of the cost of end-of-life care, many of the dollars spent yearly are focused on the treatment of chronic diseases like diabetes. The estimated yearly cost of diabetes care was $245 billion in the U.S. in 2012, the last year for which numbers have been reported. $50 billion of that was related to prescription drug purchases.Read More »
Battle between two GLP-1 receptor agonists proves semaglutide achieves favorable HbA1c levels, decreased mean body weight.Read More »
Non-adherence to Metformin Versus Therapeutic Failure: When is it Appropriate to Switch to Second-Line Therapies?
Patients who skipped initial treatment with metformin and were instead started on second-line antihyperglycemic medication more likely to need dual therapy or insulin to control T2.Read More »
Patient specific considerations have to be taken into account prior to choosing GLP-1 agonist or SGLT2 inhibitor as second-line anti-hyperglycemic agent.Read More »
Patients projected to have increase in body mass index also likely to develop increased plasma glucose levels and have diminished insulin response.Read More »